Related Experiment Video
Updated: Dec 27, 2025
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)]
Caicun Zhou1, Jie Wang2, Hong Bu3
1Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China.
Abstract:
Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer, most NSCLC patients are at advanced stage at the time of diagnosis. For patients without sensitive driven-oncogene mutations, chemotherapy is still the main treatment at present, the overall prognosis is poor. Improving outcomes and obtaining long-term survival are the most urgent needs of patients with advanced NSCLC. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors (ICIs), especially targeting programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1), have made a breakthrough in the treatment of NSCLC, beneficial to patients' survival and changed the treatment pattern for NSCLC. It shows more and more important role in the treatment of NSCLC. Led by NSCLC expert committee of Chinese society of clinical oncology (CSCO), relevant experts in this field were organized. On the basis of referring to domestic and foreign literature, systematically evaluating the results of Chinese and foreign clinical trials, and combining the experiences of the experts, the experts group reached an agreement to develop this consensus. It will guide domestic counterparts for better application of ICIs to treat NSCLC.
Insights
Immune checkpoint inhibitors targeting PD-1/PD-L1 offer a breakthrough for advanced non-small cell lung cancer (NSCLC) patients without specific mutations. This consensus guides the optimal use of these immunotherapies to improve patient survival and outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Trial Analysis
Background:
- Non-small cell lung cancer (NSCLC) is the most common type, often diagnosed at advanced stages.
- Chemotherapy remains the primary treatment for NSCLC patients lacking sensitive oncogene mutations, with generally poor prognoses.
- Improving long-term survival for advanced NSCLC patients is a critical unmet need.
Framework:
- Development of a consensus by the Chinese Society of Clinical Oncology (CSCO) expert committee.
- Systematic evaluation of domestic and international clinical trial data.
- Integration of expert clinical experience to inform treatment strategies.
Implementation:
- Focus on immune checkpoint inhibitors (ICIs), particularly those targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1).
- Application of ICIs has demonstrated significant breakthroughs in NSCLC treatment.
- These therapies have altered the treatment landscape and improved patient survival.
Implications:
- The consensus aims to guide Chinese clinicians in the effective application of ICIs for NSCLC.
- Enhanced utilization of immunotherapy is expected to improve treatment outcomes for advanced NSCLC.
- This initiative addresses the urgent need for better therapeutic options in NSCLC management.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy